LATE BREAKING CLINICAL TRIAL (JCS 2017) : Midterm Outcomes With a Self-Expandable Transcatheter Heart Valve in Japanese Patients With Symptomatic Severe Aortic Stenosis

• Sawa Yoshiki

  Osaka University Hospital

• Torikai Kei

  Osaka University Hospital

• Kobayashi Junjiro

  National Cerebral and Cardiovascular Center

• Niinami Hiroshi

  Saitama Medical University International Medical Center

• Kuratani Toru

  Osaka University Hospital

• Maeda Koichi

  Osaka University Hospital

• Kanzaki Hideaki

  National Cerebral and Cardiovascular Center

• Komiyama Nobuyuki

  Saitama Medical University International Medical Center

• Tanaka Yutaka

  Shonan Kamakura General Hospital

• Zhang Angie

  Medtronic

• Saito Shigeru

  Shonan Kamakura General Hospital

書誌事項

タイトル別名

• Midterm Outcomes With a Self-Expandable Transcatheter Heart Valve in Japanese Patients With Symptomatic Severe Aortic Stenosis

抄録

Background:Transcatheter aortic valve implantation (TAVI) is a viable alternative to surgical aortic valve replacement in high-risk or inoperable patients with aortic stenosis (AS). Here we report the midterm outcomes of high-risk Japanese patients with severe AS who underwent TAVI with a self-expandable TAV. Methods and Results:The CoreValve Japan Trial was a prospective, multicenter trial of the CoreValve System. A group of 55 patients (mean age 82.5±5.5 years, 30.9% male, 100% NYHA class III/IV, STS 8.0±4.2%) were enrolled in the 26-mm/29-mm CoreValve study, and 20 patients (mean age 81.0±6.6 years, 5.0% male, 100% NYHA class III/IV, STS 7.0±3.3%) were enrolled in the 23-mm CoreValve study, which started 1 year later. For the 26-mm/29-mm cohort, the 3-year all-cause mortality rate was 32.6%; major stroke was 15.4%. Mean pressure gradient (MPG), effective orifice area (EOA), and NYHA class showed sustained improvement. Paravalvular regurgitation (PVR) at 3 years was 28.6% (none), 25.7% (trace), 40.0% (mild), 5.7% (moderate), and 0.0% (severe). For the 23-mm cohort, the 2-year all-cause mortality rate was 5.0%; major stroke was 5.0%. MPG, EOA, and NYHA class showed sustained improvement. PVR at 2 years was 16.7% (none), 33.3% (trace), 44.4% (mild), 5.6% (moderate), and 0.0% (severe). Conclusions:TAVI with the CoreValve System was associated with sustained clinical and functional cardiac improvement in high surgical risk Japanese patients with severe AS. (Clinicaltrials.gov Identifiers: NCT01437098 and NCT01634269.)

収録刊行物

• Circulation Journal

  Circulation Journal 81 (8), 1108-1115, 2017

  一般社団法人 日本循環器学会

キーワード

• Aortic valve stenosis
• Midterm follow-up
• Transcatheter aortic valve implantation

詳細情報

• CRID: 1390001205107012352
• NII論文ID: 130005859043
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.cj-17-0112
• ISSN: 13474820
• ISSN: 13469843
• NDL書誌ID: 028377647
• PubMed: 28321003
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I028377647
• Web Site: https://www.jstage.jst.go.jp/article/circj/81/8/81_CJ-17-0112/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2018113069
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可